RealSeq Biosciences
“... when working with low amounts of RNA, RealSeq was the only method that preserved high levels of complexity.".
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Seed | |
| Total Funding | 000k | ||
Related Content
RealSeq Biosciences, Inc. is pioneering the field of RNA fragmentomics to revolutionize diagnostic capabilities. Operating in the biotechnology sector, RealSeq serves healthcare providers, research institutions, and diagnostic labs by offering advanced RNA analysis tools. The company's core product, the RiboMarker platform, enables the detection and analysis of RNA fragments from virtually any biological sample, providing deeper insights and more accurate diagnostics compared to traditional DNA analysis. RealSeq's business model is centered around the development and commercialization of its proprietary RNA fragmentomics technology, generating revenue through the sale of diagnostic kits and services. By unlocking the potential of RNA fragmentomics, RealSeq aims to improve health outcomes and advance next-generation diagnostics.
Keywords: RNA fragmentomics, diagnostics, RiboMarker, biotechnology, healthcare, research, biological samples, biomarkers, transcriptome, disease detection.